Increased matrix metalloproteinase 9 activity in mild cognitive impairment

Journal of Neuropathology and Experimental Neurology

Volumn 68, Issue 12, 2009, Pages 1309-1318

  Bruno, Martin A ^a,b   Mufson, Elliott J ^c   Wuu, Joanne ^c,d   Cuello, A Claudio ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b Universidad Catolica de Cuyo   (Argentina)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Cognition; Matrix metalloproteinase 9; Mild cognitive impairment; Nerve growth factor; Nerve growth factor precursor

Indexed keywords

GELATINASE B; NERVE GROWTH FACTOR; PROTEINASE; GELATINASE A;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EXTRACELLULAR SPACE; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PARIETAL LOBE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; SCORING SYSTEM; BRAIN; COGNITIVE DEFECT; ENZYMOLOGY; METABOLISM; NEUROPSYCHOLOGICAL TEST; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NERVE GROWTH FACTOR; NEUROPSYCHOLOGICAL TESTS;

EID: 73349089956     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181c22569     Document Type: Article

References (72)

1. Mesulam MM, Mufson EJ, Wainer BH, et al. Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 1983;10:1185-1201
2. Mufson EJ, Counts SE, Perez SE, et al. Cholinergic system during the progression of Alzheimer's disease: Therapeutic implications. Expert Rev Neurother 2008;8:1703-1718
3. Appel SH. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann Neurol 1981;10: 499-505
4. Mufson EJ, Ma SY, Cochran EJ, et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 2000;427: 19-30
5. Mufson EJ, Ma SY, Dills J, et al. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol 2002;443:136-153
6. Peng S, Wuu J, Mufson EJ, et al. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuro-pathol Exp Neurol 2004;63:641-649
7. Fahnestock M, Michalski B, Xu B, et al. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 2001;18:210-220
8. Thoenen H. Neurotrophins and neuronal plasticity. Science 1995;270: 593-598
9. Cuello AC. Effects of trophic factors on the CNS cholinergic phenotype. Prog Brain Res 1996;109:347-358
10. Bruno MA, Cuello AC. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci U S A 2006;103: 6735-6740
11. Bruno MA, Leon WC, Fragoso G, et al. Amyloid A-induced NGF dysmetabolism in Alzheimer's disease. J Neuropathol Exp Neurol 2009; 68:857-869
12. Van den Steen PE, Dubois B, Nelissen I, et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002;37:375-536
13. Beuche W, Yushchenko M, Mader M, et al. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport 2000;11:3419-3422
14. Deb S, Gottschall PE. Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem 1996;66:1641-1647
15. Deb S, Wenjun ZJ, Gottschall PE. Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes. Brain Res 2003;970:205-213
16. Roher AE, Kasunic TC, Woods AS, et al. Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. Biochem Biophys Res Commun 1994;205:1755-1761
17. Backstrom JR, Lim GP, Cullen MJ, et al. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 1996; 16:7910-7919
18. Yan P, Hu X, Song H, et al. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 2006;281:24566-24574
19. Asahina M, Yoshiyama Y, Hattori T. Expression of matrix metallo-proteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin Neuropathol 2001;20:60-63
20. Lorenzl S, Albers DS, Relkin N, et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int 2003;43:191-196
21. Lorenzl S, Buerger K, Hampel H, et al. Profiles of matrix metallo-proteinases and their inhibitors in plasma of patients with dementia. Int Psychogeriatr 2008;20:67-76
22. Backstrom JR, Miller CA, Tokes ZA. Characterization of neutral pro-teinases from Alzheimer-affected and control brain specimens: Identification of calcium-dependent metalloproteinases from the hippocampus. J Neurochem 1992;58:983-992
23. Gilmor ML, Erickson JD, Varoqui H, et al. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 1999;411:693-704
24. Kordower JH, Chu Y, Stebbins GT, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 2001;49:202-213
25. Mufson EJ, Lavine N, Jaffar S, et al. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Exp Neurol 1997;146:91-103
26. DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002;51:145-155
27. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198-205
28. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH stroke scale. Arch Neurol 1989;46:660-662
29. Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale. Extension to non-neurologists in the context of a clinical trial. Stroke 1997;28:307-310
30. Bennett DA, Shannon KM, Beckett LA, et al. Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale. Neurology 1997;49:1580-1587
31. Bennett DA, Shannon KM, Beckett LA, et al. Dimensionality of par-kinsonian signs in aging and Alzheimer's disease. J Gerontol A Biol Sci Med Sci 1999;54:M191-96
32. Folstein MF, Folstein SE, McHugh PR. BMini-mental state.[ A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98
33. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuro-psychological assessment of Alzheimer's disease. Neurology 1989;39: 1159-1165
34. Beckett LA, Wilson RS, Bennett DA, et al. Around the WORLD backward: An algorithm for scoring the MMSE WORLD item. Neurology 1997;48:1733-1734
35. Pittman J, Andrews H, Tatemichi T, et al. Diagnosis of dementia in a heterogeneous population. A comparison of paradigm-based diagnosis and physician's diagnosis. Arch Neurol 1992;49:461-467
36. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944
37. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194
38. DeKosky ST, Harbaugh RE, Schmitt FA, et al. Cortical biopsy in Alzheimer's disease: Diagnostic accuracy and neurochemical, neuro-pathological, and cognitive correlations. Intraventricular Bethanecol Study Group. Ann Neurol 1992;32:625-632
39. Albert M, Smith LA, Scherr PA, et al. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int J Neurosci 1991;57:167-178
40. Mufson EJ, Chen EY, Cochran EJ, et al. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol 1999; 158:469-490
41. Cochran EJ, Fox JH, Mufson EJ. Severe panencephalic Pick's disease with Alzheimer's disease-like neuropil threads and synaptophysin immunoreactivity. Acta Neuropathol 1994;88:479-484
42. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486
43. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259
44. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997;18:S1-S2
45. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980;102:196-202
46. Toth M, Fridman R. Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. Methods Mol Med 2001;57:163-263
47. Barnes LL, Wilson RS, Schneider JA, et al. Gender, cognitive decline, and risk of AD in older persons. Neurology 2003;60:1777-1781
48. Wisniewski HM, Rabe A. Discrepancy between Alzheimer-type neuro-pathology and dementia in persons with Down's syndrome. Ann N Y Acad Sci 1986;477:247-260
49. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of non-demented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30:1026-1036
50. Geddes JW, Tekirian TL, Soultanian NS, et al. Comparison of neuro-pathologic criteria for the diagnosis of Alzheimer's disease. Neurobiol Aging 1997;18:S99YS105
51. Mesulam M, Shaw P, Mash D, et al. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 2004;55:815-828
52. Sassin I, Schultz C, Thal DR, et al. Evolution of Alzheimer's diseaseYrelated cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol 2000;100:259-269
53. Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, et al. Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am J Pathol 2000;157:623-636
54. Counts SE, Mufson EJ. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J Neuropathol Exp Neurol 2005;64:263-272
55. Counts SE, Nadeem M, Wuu J, et al. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann Neurol 2004; 56:520-531
56. Zhan SS, Kamphorst W, Van Nostrand WE, et al. Distribution of neuronal growth-promoting factors and cytoskeletal proteins in altered neurites in Alzheimer's disease and non-demented elderly. Acta Neuro-pathol 1995;89:356-362
57. Ginsberg SD, Che S, Counts SE, et al. Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal fore-brain neurons in mild cognitive impairment and Alzheimer's disease. J Neurochem 2006;96:1401-1408
58. Kaplan DR, Miller FD. Neurobiology: A move to sort life from death. Nature 2004;427:798-799
59. Volosin M, Song W, Almeida RD, et al. Interaction of survival and death signaling in basal forebrain neurons: Roles of neurotrophins and proneurotrophins. J Neurosci 2006;26:7756-7766
60. Lee R, Kermani P, Teng KK, et al. Regulation of cell survival by secreted proneurotrophins. Science 2001;294:1945-1948
61. Nykjaer A, Lee R, Teng KK, et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature 2004;427:843-848
62. Clewes O, Fahey MS, Tyler SJ, et al. Human ProNGF: Biological effects and binding profiles at TrkA, P75NTR and sortilin. J Neurochem 2008; 107:1124-1135
63. Costantini C, Weindruch R, Della VG, et al. A TrkA-to-p75NTR molecular switch activates amyloid beta-peptide generation during aging. Biochem J 2005;391:59-67
64. Yin KJ, Cirrito JR, Yan P, et al. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J Neurosci 2006;26:10939-10948
65. Farfara D, Lifshitz V, Frenkel D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med 2008;12:762-780
66. Eikelenboom P, Veerhuis R, Familian A, et al. Neuroinflammation in plaque and vascular beta-amyloid disorders: Clinical and therapeutic implications. Neurodegener Dis 2008;5:190-193
67. McGeer PL, McGeer EG. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195-218
68. Beckman JS, Chen J, Crow JP, et al. Reactions of nitric oxide, super-oxide and peroxynitrite with superoxide dismutase in neurodegeneration. Prog Brain Res 1994;103:371-380
69. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am J Physiol 1996;271:C1424-37
70. Luth HJ, Holzer M, Gartner U, et al. Expression of endothelial and in-ducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: Evidence for an induction by amyloid pathology. Brain Res 2001;913:57-67
71. Luth HJ, Apelt J, Ihunwo AO, et al. Degeneration of beta-amyloidY associated cholinergic structures in transgenic APP SW mice. Brain Res 2003;977:16-22
72. Hock C, Heese K, Muller-Spahn F, et al. Increased CSF levels of nerve growth factor in patients with Alzheimer's disease. Neurology 2000;54: 2009-2011